Granisetron hydrochloride syrup uses

Information about Granisetron Granisetron Uses Granisetron is used to prevent nausea and vomiting due to chemotherapy.

Official websites use. Share sensitive information only on official, secure websites. Granisetron is used to prevent nausea and vomiting caused by cancer chemotherapy and radiation therapy. Granisetron is in a class of medications called 5-HT 3 receptor antagonists. It works by blocking serotonin, a natural substance in the body that causes nausea and vomiting. Granisetron comes as a tablet to take by mouth. When taken to prevent nausea and vomiting caused by chemotherapy, granisetron is usually taken 1 hour before chemotherapy is begun.

Granisetron hydrochloride syrup uses

Chemotherapy-induced nausea and vomiting CINV , prevention:. Highly emetogenic chemotherapy:. Moderately emetogenic chemotherapy:. Low-emetogenic chemotherapy:. Consult drug interactions database for more information. For additional information see "Granisetron: Drug information". Note: Granisol oral solution has been discontinued in the United States for more than 1 year. Oral: 2 mg once daily up to 1 hour before chemotherapy or 1 mg twice daily; the first 1 mg dose should be administered up to 1 hour before chemotherapy with the second 1 mg dose 12 hours later. Administer only on the day s chemotherapy is administered. May also be administered in combination with a neurokinin 1 NK 1 receptor antagonist antiemetic regimen. Transdermal patch: Prophylaxis of chemotherapy-related emesis: Apply 1 patch at least 24 hours prior to chemotherapy; may be applied up to 48 hours before chemotherapy. Remove patch a minimum of 24 hours after chemotherapy completion. Maximum duration: Patch may be worn up to 7 days, depending on chemotherapy regimen duration.

Transdermal Sancuso : Apply patch by pressing down firmly to clean, dry, nearly hairless, intact skin on upper outer arm; smooth down with fingers.

Granisetron is a serotonin 5-HT 3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its main effect is to reduce the activity of the vagus nerve , which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors. Granisetron was developed by chemists working at the British drug company Beecham c.

This page contains brief information about granisetron and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. FDA label information for this drug is available at DailyMed. Granisetron is approved to be used alone or with other drugs to prevent:. Granisetron is also available in a different form called granisetron hydrochloride. MedlinePlus Information on Granisetron - A lay language summary of important information about this drug that may include the following:. Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Granisetron hydrochloride syrup uses

Granisetron is a serotonin 5-HT 3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its main effect is to reduce the activity of the vagus nerve , which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness.

Huawei 521 modem

Wash hands thoroughly after applying. Consensus guidelines for the management of postoperative nausea and vomiting. SUBQ: 10 mg as a single dose. Antagonists: Metitepine methiothepin Mianserin. Granisetron tablet [prescribing information]. Anesth Analg. It is important to keep all medication out of sight and reach of children as many containers such as weekly pill minders and those for eye drops, creams, patches, and inhalers are not child-resistant and young children can open them easily. Saudi Journal of Anaesthesia. Granisetron pronounced as gra ni' se tron. Day of chemotherapy: Administer prior to chemotherapy and in combination with an NK 1 receptor antagonist, dexamethasone, and olanzapine. Graniset Sun Pharmaceutical Industries Ltd. Injection site nodules occurred in less than one-fifth of patients, usually persisting for 15 to 21 days. Isaksson M, Jansson L.

Official websites use. Share sensitive information only on official, secure websites.

Analogue-based Drug Discovery. Frequency not defined any route of administration : Cardiovascular: Angina pectoris, atrioventricular block, cardiac arrhythmia, ECG abnormality, hypotension, sinus bradycardia, ventricular ectopy includes nonsustained ventricular tachycardia. Transdermal patch: Prophylaxis of chemotherapy-related emesis: Apply 1 patch at least 24 hours prior to chemotherapy; may be applied up to 48 hours before chemotherapy. Emegran 3 Biochem Pharmaceutical Industries. Brand Names: International. The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Moderately emetogenic chemotherapy:. Administration: Pediatric Oral: Administer 30 minutes to 1 hour prior to chemotherapy and repeat in 12 hours Ref. Oral: 2 mg once daily administered 1 to 2 hours prior to each fraction of radiation; administer in combination with dexamethasone Ref. Note: Guidelines do not state a preference for which 5-HT 3 receptor antagonist should be used in this setting; however, palonosetron may be preferred Ref. Sancuso granisetron transdermal [prescribing information]. Stable for 91 days refrigerated Nahata